| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
8,340 |
7,490 |
$729K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
16,537 |
4,565 |
$659K |
| 80053 |
Comprehensive metabolic panel |
39,149 |
31,274 |
$486K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
3,550 |
3,275 |
$464K |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,905 |
3,576 |
$378K |
| 80050 |
General health panel |
7,782 |
7,382 |
$367K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
5,018 |
4,388 |
$328K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
1,052 |
1,041 |
$258K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
3,478 |
2,603 |
$245K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,410 |
2,894 |
$207K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
6,338 |
4,897 |
$204K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
8,279 |
6,436 |
$202K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
33,789 |
26,893 |
$200K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
11,260 |
9,749 |
$198K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
690 |
667 |
$185K |
| 86008 |
|
789 |
607 |
$182K |
| 80061 |
Lipid panel |
14,992 |
11,997 |
$163K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
2,947 |
2,700 |
$158K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
1,006 |
933 |
$154K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
5,032 |
4,003 |
$151K |
| 84443 |
Thyroid stimulating hormone (TSH) |
15,853 |
12,287 |
$149K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
1,316 |
1,230 |
$144K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
3,385 |
2,866 |
$135K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
1,032 |
479 |
$134K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
3,380 |
2,861 |
$134K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
948 |
847 |
$107K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
10,902 |
9,709 |
$106K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
336 |
312 |
$102K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
580 |
421 |
$94K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
3,546 |
1,075 |
$92K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
2,487 |
2,396 |
$91K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,338 |
1,254 |
$90K |
| 71046 |
Radiologic examination, chest; 2 views |
5,198 |
4,820 |
$90K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
8,721 |
6,555 |
$89K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
662 |
538 |
$83K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
10,670 |
8,576 |
$81K |
| 59025 |
Fetal non-stress test |
396 |
322 |
$77K |
| 81025 |
|
8,710 |
7,863 |
$74K |
| 86901 |
|
3,245 |
2,905 |
$71K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
183 |
169 |
$66K |
| 97162 |
|
578 |
536 |
$64K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
7,880 |
6,273 |
$63K |
| 85027 |
|
11,126 |
8,770 |
$63K |
| 87070 |
|
7,201 |
5,078 |
$62K |
| 97161 |
|
1,019 |
890 |
$55K |
| 83690 |
|
7,818 |
6,795 |
$54K |
| 81001 |
|
16,151 |
13,851 |
$52K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,732 |
2,284 |
$51K |
| 82150 |
|
7,759 |
6,872 |
$50K |
| 84439 |
|
6,168 |
4,950 |
$49K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
1,252 |
1,195 |
$49K |
| 71045 |
Radiologic examination, chest; single view |
5,830 |
5,241 |
$48K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,118 |
1,013 |
$42K |
| 82607 |
|
3,299 |
2,656 |
$39K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,419 |
1,544 |
$38K |
| 82553 |
|
4,284 |
3,655 |
$38K |
| 86141 |
|
3,404 |
2,702 |
$36K |
| 84484 |
|
4,925 |
3,959 |
$36K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
164 |
151 |
$36K |
| 85730 |
|
6,597 |
5,906 |
$35K |
| 72110 |
|
1,085 |
1,044 |
$35K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
712 |
567 |
$35K |
| 82728 |
|
3,218 |
2,512 |
$34K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,501 |
2,104 |
$32K |
| 83880 |
|
1,444 |
1,274 |
$31K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,004 |
1,821 |
$31K |
| 87186 |
|
4,938 |
4,051 |
$29K |
| 82565 |
|
2,537 |
2,118 |
$28K |
| 80320 |
|
1,614 |
1,458 |
$28K |
| 74018 |
|
1,403 |
1,300 |
$28K |
| 85610 |
|
7,701 |
6,613 |
$27K |
| 84145 |
|
1,448 |
1,326 |
$27K |
| 82948 |
|
4,067 |
2,625 |
$27K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,027 |
1,790 |
$26K |
| 82550 |
|
5,089 |
4,256 |
$26K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
5,171 |
4,422 |
$26K |
| 73630 |
|
1,012 |
937 |
$26K |
| 87040 |
|
1,722 |
1,567 |
$25K |
| 97001 |
|
569 |
528 |
$24K |
| 87077 |
|
2,773 |
2,368 |
$23K |
| 87806 |
|
932 |
828 |
$22K |
| 76642 |
|
801 |
770 |
$21K |
| 70486 |
|
165 |
161 |
$21K |
| 83540 |
|
3,932 |
3,116 |
$21K |
| 82746 |
|
1,970 |
1,574 |
$20K |
| 83735 |
|
4,508 |
3,291 |
$20K |
| 86003 |
|
334 |
176 |
$19K |
| 80347 |
|
959 |
796 |
$19K |
| 49452 |
|
226 |
177 |
$19K |
| 77066 |
Tomosynthesis, mammo |
275 |
265 |
$18K |
| 84702 |
|
1,817 |
1,427 |
$18K |
| 80329 |
|
1,079 |
946 |
$18K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
1,987 |
1,903 |
$18K |
| 86803 |
|
1,299 |
1,124 |
$18K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
11,036 |
8,459 |
$17K |
| 83605 |
|
1,815 |
1,631 |
$17K |
| 86850 |
|
2,671 |
2,384 |
$17K |
| 97165 |
|
305 |
265 |
$17K |
| 83550 |
|
2,325 |
1,868 |
$16K |
| 73610 |
|
861 |
805 |
$16K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
609 |
561 |
$16K |
| 73564 |
|
481 |
458 |
$15K |
| 73030 |
|
735 |
685 |
$15K |
| 84153 |
|
975 |
809 |
$14K |
| 82785 |
|
825 |
644 |
$14K |
| 80074 |
|
295 |
262 |
$14K |
| 80047 |
|
509 |
440 |
$13K |
| 82570 |
|
2,914 |
2,364 |
$13K |
| 80326 |
|
671 |
607 |
$12K |
| 80349 |
|
631 |
589 |
$12K |
| 84403 |
|
424 |
377 |
$11K |
| 86225 |
|
1,008 |
791 |
$11K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
88 |
77 |
$11K |
| 87088 |
|
1,420 |
1,155 |
$11K |
| 87340 |
|
1,117 |
988 |
$11K |
| 82947 |
|
1,401 |
1,230 |
$10K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
559 |
503 |
$10K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
3,367 |
3,142 |
$10K |
| 87015 |
|
1,497 |
1,173 |
$10K |
| 88312 |
|
1,067 |
989 |
$10K |
| 72050 |
|
427 |
408 |
$10K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
492 |
464 |
$10K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
5,654 |
4,939 |
$10K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
111 |
106 |
$10K |
| 85007 |
|
2,835 |
2,384 |
$9K |
| 86706 |
|
923 |
812 |
$9K |
| 86900 |
|
3,247 |
2,907 |
$9K |
| 83516 |
|
414 |
333 |
$9K |
| 86039 |
|
970 |
782 |
$9K |
| 87205 |
|
2,394 |
1,966 |
$9K |
| 84132 |
|
1,094 |
964 |
$9K |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
25 |
24 |
$9K |
| 72141 |
|
40 |
39 |
$9K |
| 87899 |
|
1,287 |
374 |
$9K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
179 |
171 |
$9K |
| 87507 |
|
12 |
12 |
$8K |
| 81003 |
|
4,127 |
3,667 |
$8K |
| 82435 |
|
877 |
811 |
$8K |
| 88304 |
|
345 |
322 |
$8K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
297 |
238 |
$8K |
| 85379 |
|
833 |
780 |
$8K |
| 86780 |
|
443 |
418 |
$8K |
| 82247 |
|
1,466 |
914 |
$7K |
| 95957 |
|
340 |
311 |
$7K |
| C1769 |
Guide wire |
763 |
595 |
$7K |
| 74019 |
|
353 |
322 |
$7K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
4,967 |
3,895 |
$7K |
| 82043 |
|
1,410 |
1,201 |
$7K |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
398 |
345 |
$7K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
33 |
29 |
$7K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
42 |
39 |
$7K |
| 84480 |
|
571 |
505 |
$7K |
| 80364 |
|
595 |
396 |
$7K |
| 95819 |
|
143 |
132 |
$6K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
455 |
419 |
$6K |
| 84295 |
|
959 |
872 |
$6K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
854 |
699 |
$6K |
| J2785 |
Injection, regadenoson, 0.1 mg |
28 |
28 |
$6K |
| 86708 |
|
505 |
438 |
$6K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
154 |
124 |
$6K |
| 80051 |
|
1,279 |
1,153 |
$6K |
| 80076 |
|
767 |
629 |
$6K |
| 73110 |
|
250 |
238 |
$5K |
| 84520 |
|
1,240 |
1,055 |
$5K |
| 71020 |
|
407 |
395 |
$5K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
25 |
22 |
$5K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,869 |
1,589 |
$5K |
| 85652 |
|
1,931 |
1,712 |
$5K |
| 62323 |
|
26 |
25 |
$5K |
| 86704 |
|
472 |
408 |
$5K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
365 |
340 |
$5K |
| 82248 |
|
1,012 |
668 |
$5K |
| Q3014 |
Telehealth originating site facility fee |
742 |
691 |
$5K |
| 87420 |
|
408 |
371 |
$5K |
| 87430 |
|
363 |
350 |
$5K |
| 84100 |
|
1,971 |
1,348 |
$4K |
| 73130 |
|
201 |
186 |
$4K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
29 |
29 |
$4K |
| 72070 |
|
204 |
200 |
$4K |
| 76830 |
Ultrasound, transvaginal |
108 |
100 |
$4K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
123 |
106 |
$4K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
115 |
112 |
$4K |
| 85014 |
|
1,630 |
1,317 |
$4K |
| 86592 |
|
922 |
823 |
$4K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
47 |
42 |
$4K |
| 84156 |
|
859 |
676 |
$4K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
95 |
92 |
$4K |
| 83525 |
|
460 |
273 |
$4K |
| 84146 |
|
134 |
122 |
$4K |
| 93971 |
|
100 |
88 |
$3K |
| 87045 |
|
357 |
272 |
$3K |
| 0002A |
|
215 |
209 |
$3K |
| 83970 |
|
127 |
111 |
$3K |
| 85651 |
|
1,556 |
980 |
$3K |
| 76775 |
|
167 |
161 |
$3K |
| 86480 |
|
44 |
42 |
$3K |
| J2704 |
Injection, propofol, 10 mg |
5,957 |
5,451 |
$3K |
| 84238 |
|
278 |
188 |
$3K |
| 86431 |
|
561 |
483 |
$3K |
| 82105 |
|
165 |
151 |
$3K |
| 82805 |
|
116 |
109 |
$3K |
| 84550 |
|
841 |
694 |
$3K |
| 64635 |
|
15 |
14 |
$2K |
| 82330 |
|
117 |
106 |
$2K |
| 49450 |
|
25 |
25 |
$2K |
| 36430 |
|
14 |
12 |
$2K |
| 64493 |
|
33 |
13 |
$2K |
| 76536 |
|
55 |
51 |
$2K |
| 85018 |
|
824 |
628 |
$2K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
968 |
829 |
$2K |
| 87210 |
|
391 |
374 |
$2K |
| 0001A |
|
189 |
182 |
$2K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
381 |
333 |
$2K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
2,692 |
2,211 |
$2K |
| 83615 |
|
607 |
341 |
$2K |
| 73502 |
|
58 |
57 |
$2K |
| 74000 |
|
107 |
99 |
$2K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
4,562 |
3,937 |
$2K |
| 87634 |
|
23 |
22 |
$2K |
| 77065 |
Tomosynthesis, mammo |
30 |
25 |
$2K |
| 82784 |
|
214 |
189 |
$1K |
| 86376 |
|
90 |
79 |
$1K |
| 77080 |
|
59 |
52 |
$1K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
12 |
12 |
$1K |
| 71010 |
|
159 |
153 |
$1K |
| 82670 |
|
45 |
41 |
$1K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
309 |
106 |
$1K |
| 87653 |
|
25 |
25 |
$1K |
| 84481 |
|
176 |
128 |
$1K |
| 96376 |
|
215 |
172 |
$1K |
| 86757 |
|
37 |
26 |
$1K |
| 84144 |
|
42 |
26 |
$1K |
| 87046 |
|
559 |
375 |
$1K |
| 80165 |
|
101 |
87 |
$1K |
| 87493 |
|
83 |
40 |
$987.05 |
| 90714 |
|
114 |
103 |
$972.81 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
553 |
388 |
$931.08 |
| 77062 |
|
12 |
12 |
$901.17 |
| 86256 |
|
56 |
55 |
$775.17 |
| 83655 |
|
44 |
44 |
$725.76 |
| 80164 |
|
81 |
62 |
$709.41 |
| 86920 |
|
16 |
14 |
$680.00 |
| 84450 |
|
206 |
148 |
$677.52 |
| 73080 |
|
26 |
26 |
$654.71 |
| 72170 |
|
44 |
42 |
$642.14 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
103 |
92 |
$616.85 |
| 99152 |
|
293 |
229 |
$601.13 |
| 88307 |
|
26 |
24 |
$583.00 |
| 86666 |
|
45 |
36 |
$581.20 |
| 83001 |
|
24 |
24 |
$566.53 |
| 75984 |
|
385 |
309 |
$560.02 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
3,386 |
2,516 |
$524.86 |
| 72100 |
|
28 |
28 |
$518.70 |
| 84436 |
|
177 |
133 |
$495.25 |
| 86200 |
|
34 |
33 |
$472.30 |
| 72120 |
|
17 |
16 |
$465.81 |
| 73120 |
|
35 |
25 |
$464.15 |
| 86618 |
|
33 |
24 |
$442.08 |
| 88342 |
|
30 |
29 |
$435.60 |
| G0378 |
Hospital observation service, per hour |
231 |
187 |
$421.60 |
| 85049 |
|
257 |
229 |
$418.47 |
| 87081 |
|
55 |
52 |
$385.77 |
| 86235 |
|
14 |
12 |
$384.15 |
| 36000 |
|
176 |
173 |
$381.31 |
| 84703 |
|
49 |
45 |
$364.33 |
| 85045 |
|
246 |
174 |
$361.90 |
| 83721 |
|
98 |
92 |
$353.78 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
165 |
143 |
$338.03 |
| 86709 |
|
26 |
26 |
$321.40 |
| 73590 |
|
16 |
14 |
$304.63 |
| 87631 |
|
21 |
16 |
$303.84 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
932 |
806 |
$289.73 |
| 82310 |
|
27 |
24 |
$286.58 |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
30 |
29 |
$266.71 |
| 82950 |
|
45 |
42 |
$252.22 |
| 86762 |
|
12 |
12 |
$246.60 |
| 84460 |
|
78 |
45 |
$237.22 |
| 73560 |
|
13 |
12 |
$229.74 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
236 |
211 |
$206.73 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
548 |
344 |
$187.43 |
| 73140 |
|
12 |
12 |
$176.00 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
478 |
419 |
$172.32 |
| 76882 |
|
13 |
12 |
$172.29 |
| 84075 |
|
48 |
29 |
$165.36 |
| J2060 |
Injection, lorazepam, 2 mg |
311 |
260 |
$164.45 |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
39 |
13 |
$158.14 |
| 86800 |
|
14 |
12 |
$136.26 |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
267 |
81 |
$134.94 |
| 87324 |
|
13 |
13 |
$132.17 |
| 76937 |
|
39 |
29 |
$128.17 |
| 86677 |
|
20 |
13 |
$124.32 |
| 94150 |
|
129 |
101 |
$117.49 |
| 93017 |
|
30 |
29 |
$111.80 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
285 |
246 |
$102.33 |
| 83986 |
|
14 |
13 |
$90.48 |
| 84155 |
|
34 |
27 |
$74.63 |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
30 |
29 |
$70.66 |
| 93296 |
|
13 |
12 |
$59.45 |
| J1644 |
Injection, heparin sodium, per 1000 units |
409 |
245 |
$51.59 |
| 89051 |
|
18 |
12 |
$47.16 |
| J1815 |
Injection, insulin, per 5 units |
119 |
75 |
$36.88 |
| 97116 |
|
21 |
12 |
$20.09 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
156 |
110 |
$16.40 |
| 82040 |
|
17 |
13 |
$14.16 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
96 |
69 |
$6.65 |
| 94664 |
|
71 |
64 |
$6.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
33 |
27 |
$0.11 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
13 |
13 |
$0.06 |
| Q0245 |
Injection, bamlanivimab and etesevimab, 2100 mg |
31 |
22 |
$0.01 |
| A9270 |
Non-covered item or service |
174 |
83 |
$0.00 |
| 99153 |
Mod sedat endo service >5yrs |
70 |
55 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
2,559 |
2,330 |
$0.00 |
| 94760 |
|
22 |
14 |
$0.00 |
| 41899 |
Unlisted procedure, dentoalveolar structures |
32 |
29 |
$0.00 |
| 97802 |
|
13 |
12 |
$0.00 |
| J3490 |
Unclassified drugs |
16 |
14 |
$0.00 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,339 |
1,095 |
$0.00 |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
122 |
118 |
$0.00 |
| 99001 |
|
1,078 |
706 |
$0.00 |
| Q0243 |
Injection, casirivimab and imdevimab, 2400 mg |
16 |
16 |
$0.00 |
| 93356 |
|
31 |
25 |
$0.00 |